Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Now Covered by Craig Hallum

Research analysts at Craig Hallum initiated coverage on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a note issued to investors on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $4.00 price target on the stock. Craig Hallum’s price target suggests a potential upside of 343.46% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, May 6th.

Lineage Cell Therapeutics Stock Performance

LCTX opened at $0.90 on Tuesday. The stock has a market cap of $170.30 million, a P/E ratio of -6.44 and a beta of 1.29. Lineage Cell Therapeutics has a 52-week low of $0.77 and a 52-week high of $1.61.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. The firm had revenue of $1.41 million during the quarter, compared to analysts’ expectations of $1.28 million. Lineage Cell Therapeutics had a negative net margin of 295.59% and a negative return on equity of 34.92%. Equities research analysts predict that Lineage Cell Therapeutics will post -0.12 EPS for the current year.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Large investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD raised its position in shares of Lineage Cell Therapeutics by 77.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 161,314 shares of the company’s stock worth $239,000 after acquiring an additional 70,418 shares during the last quarter. Comerica Bank lifted its holdings in Lineage Cell Therapeutics by 84,745.8% in the first quarter. Comerica Bank now owns 250,295 shares of the company’s stock valued at $370,000 after buying an additional 250,000 shares during the period. Fifth Third Wealth Advisors LLC acquired a new stake in Lineage Cell Therapeutics during the 1st quarter worth about $30,000. DCF Advisers LLC raised its position in shares of Lineage Cell Therapeutics by 14.5% in the 4th quarter. DCF Advisers LLC now owns 94,751 shares of the company’s stock worth $103,000 after acquiring an additional 12,000 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in shares of Lineage Cell Therapeutics by 10.0% in the 2nd quarter. Renaissance Technologies LLC now owns 583,622 shares of the company’s stock valued at $582,000 after purchasing an additional 53,022 shares during the period. Institutional investors own 62.47% of the company’s stock.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.